We support reforms which will allow all Canadians to access the medicines they need when needed, equitably and consistently, as outlined in our core positions and principles, and in formal submissions.
CADTH Advisory Panel:
BMC Submission on Potential Pan-Canadian Formulary (February 25, 2022)
National Strategy for Drugs for Rare Diseases:
Op-ed: Canada must act to fund drugs for rare diseases (Ottawa Citizen, March 9, 2023)
Pharmacare Advisory Council:
BMC’s Position Points on Key Recommendations (July 2019)
Joint Discussion Paper:
Better Pharmacare For Patients: Evaluating Policy Options (June 2018) (Français)
We support a strong regulatory framework for pharmaceutical pricing and related assessment and negotiation processes which ensure value and deliver the best possible care for patients in a timely manner.
Submission to the pan-Canadian Pharmaceutical Alliance: pCPA Temporary Access Process (pTAP) (August 16, 2023)
We a support a national regulatory framework which protects Canadian patients, including addressing supply issues like drug shortages which put patients at risk.
Submission to Health Canada on improving access to drugs and other health products in Canada – drug supply (August 31, 2023)
We seek pharmaceutical assessment which incorporates patient-driven evidence and perspectives and leads to improved patient care.
Health Technology Assessment in Canada: Improving the System and Ensuring the Patient Voice is Heard (February 2014)